drugset / Trial / NCT05664919
Efficacy and Safety of Anti-COVID-19 Antibody SA58 Nasal Spray to Prevent Infection in High-risk Populations
Non-randomizedParallel-groupOpen-labelPrevention
Summary
This is an open, blank controlled clinical trial to evaluate the efficacy and safety of SA58 nasal spray in the prevention COVID-19 infection among health care workers at high risk of SARS-CoV-2 infection.
Timeline
- Start
- 2022-10-30
- Primary completion
- 2022-12-31
- Completion
- 2023-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SA58 | Protein / enzyme biologic | 5 mg/ml | Intranasal |